The Oncology Institute, Inc. TOI Specialty Pharmacy — Direct costs
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by The Oncology Institute, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization.
The official record: The Oncology Institute, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about The Oncology Institute, Inc.'s specialty pharmacy — direct costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is The Oncology Institute, Inc.'s specialty pharmacy — direct costs?
- The Oncology Institute, Inc. (TOI) reported specialty pharmacy — direct costs of $70.74M in Q1 2026.
- How has The Oncology Institute, Inc.'s specialty pharmacy — direct costs changed year-over-year?
- The Oncology Institute, Inc.'s specialty pharmacy — direct costs increased by 77.5% year-over-year, from $39.86M to $70.74M.
- What does specialty pharmacy — direct costs mean?
- This metric captures the direct expenses associated with procuring, handling, and dispensing specialty oncology medications, including the cost of goods sold and related pharmacy-specific operational outlays. It serves as a primary indicator of the cost-efficiency and margin profile of the pharmacy segment. Monitoring these costs is essential for evaluating the company's ability to manage pharmaceutical procurement pricing and supply chain overhead.